US HB6731 | 2019-2020 | 116th Congress
Status
Spectrum: Slight Partisan Bill (Republican 3-1)
Status: Introduced on May 5 2020 - 25% progression, died in committee
Action: 2020-05-05 - Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Oversight and Reform Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 5 2020 - 25% progression, died in committee
Action: 2020-05-05 - Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Oversight and Reform Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Allows an executive agency to purchase a drug approved or licensed by the Food and Drug Administration only if the drug is over 50% sourced, manufactured, and assembled in the United States. This requirement may be waived (1) if the drug is not available in sufficient quantity or quality as over 50% sourced, manufactured, and assembled in the United States; or (2) during an emergency. The U.S. Trade Representative (USTR) shall modify U.S. product coverage under all free trade agreements and the World Trade Organization Agreement on Government Procurement to exclude coverage of essential medicines and medical countermeasures. Subsequent to such modifications, the USTR shall make any necessary corresponding modifications of existing waivers and notify the Office of Management and Budget.
Title
Securing America’s Pharmaceutical Supply Chain Act
Sponsors
Rep. Pete Stauber [R-MN] | Rep. John Garamendi [D-CA] | Rep. Bob Gibbs [R-OH] | Rep. James Hagedorn [R-MN] |
History
Date | Chamber | Action |
---|---|---|
2020-05-05 | House | Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-05-05 | House | Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-05-05 | House | Introduced in House |
Subjects
Government operations and politics
Manufacturing
Prescription drugs
Public contracts and procurement
Trade agreements and negotiations
Manufacturing
Prescription drugs
Public contracts and procurement
Trade agreements and negotiations
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/6731/all-info |
Text | https://www.congress.gov/116/bills/hr6731/BILLS-116hr6731ih.pdf |